Form 4: Mirum Pharmaceuticals' Chief Scientific Officer, Pamela Vig, Reports Stock Sale to Cover Tax Obligations

Pamela Vig, Chief Scientific Officer of Mirum Pharmaceuticals, reports selling 1,379 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Summary

• On January 9, 2023, Pamela Vig, the Chief Scientific Officer of Mirum Pharmaceuticals, sold 1,379 shares of common stock at a price of $20.6223 per share.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following the transaction, Ms. Vig directly owns 27,312 shares of Mirum Pharmaceuticals' common stock.
• Ms. Vig also indirectly owns 75,000 shares through The Vig-Ancock Family Trust.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to an insider stock sale for tax purposes, indicating a neutral sentiment.

Industry Context

Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and directors. This transaction is related to tax obligations, which is a common reason for such sales.

Stakeholder Impact

• The sale of shares by a company officer could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates